Sino Medical Sciences Technology Inc. Stock Analysis 688108.SS

Sino Medical Sciences Technology, Inc. engages in the research, development, production, and sale of interventional medical devices. The company is headquartered in Tianjin, Tianjin and currently employs 649 full-time employees. The company went IPO on 2019-10-30. The firm's product pipeline covers the field of interventional therapy such as cardiovascular, cerebrovascular, and structural heart disease. The firm's main products include coronary drug stent system and balloon dilatation catheters. The firm manufactures and sells products covering two main categories: coronary intervention and neurointervention, including coronary stents, coronary balloons, neurostents, neuroballoons, and related products. These products are primarily used in interventional medical treatments such as coronary artery stenting. The firm conducts its business within the domestic market and overseas markets.